Are Uterine Polyps Cancerous? The Malignancy Risk Most Women Overestimate

Are uterine polyps cancerous? No — the overwhelming majority are benign. Population studies put the malignancy rate in uterine polyps at roughly 1 to 5 percent, and in premenopausal women it is closer to 1 to 2 percent. The risk rises with age and after menopause, reaching about 5 percent in postmenopausal women with a polyp and peaking near 10 percent in women over 70. So the honest answer is: almost never, but not never. That nuance is why the diagnosis deserves a real explanation rather than a reassuring shrug.

The fear that follows the word "polyp" is usually misplaced but not irrational. A polyp is tissue that should not be there — a focal overgrowth on the lining of the uterus, the endometrium. Most of the time that overgrowth obeys the rules of normal tissue. Occasionally it breaks them. This article explains which polyps obey and which break, how often the two happen, and what separates them at the level of a cell.

What a uterine polyp actually is

A uterine polyp is a finger-shaped projection of endometrial tissue that bulges from the inner wall of the uterus into the cavity. It has a stalk or a broad base, called the peduncle, and its own blood supply. It can be as small as 1 millimeter or as large as several centimeters. Most sit in the uterine cavity itself, and a smaller proportion sit in the cervical canal.

The key fact is that a polyp is made of the same tissue as the endometrium — glands, stroma, and blood vessels — but organized abnormally. Its glands are often irregular in shape and its stroma may be dense or fibrous. That local disorganization is the reason a polyp looks like a growth on imaging and a reason a biopsy is needed to tell benign from malignant.

Polyps are common. Autopsy and imaging series suggest they appear in roughly 10 to 25 percent of women at some point, and they are found in 2 to 5 percent of women presenting with abnormal bleeding. They are most common between ages 40 and 60, but can appear at any reproductive age and are sometimes found after menopause.

In plain terms: a polyp is a lump of the uterine lining that grew in the wrong shape, not necessarily the wrong cells.

The mechanism: why most polyps stay benign

To understand why most polyps are harmless, follow the biology of the endometrium. The uterine lining is one of the few tissues in the body that regenerates every month. It thickens under estrogen, then sheds under progesterone withdrawal. This cycle is tightly controlled by growth signals and their brakes — genes that promote cell division and genes that stop it.

A benign polyp is a local failure of that regulation without a permanent genetic break. Estrogen keeps pushing growth in a small patch of tissue, while the normal brake of progesterone is absent or reduced in that patch. The result is a focal overgrowth with intact, orderly cell architecture. Cells in a benign polyp still look like endometrial cells. They still respond to hormonal signals. They do not invade the muscle layer beneath.

A cancerous polyp is different at the level of DNA. Malignant transformation in the endometrium usually begins with loss of the tumor suppressor PTEN, which removes one brake. That is followed by other changes, including mutations in PIK3CA and KRAS, and later in TP53. Only when cells acquire the ability to invade the underlying myometrium and to spread does the lesion become carcinoma. A polyp sitting on the surface may already contain carcinoma cells, but invasion is what separates atypical hyperplasia from true cancer.

This is why the pathology report matters more than the imaging report. Imaging shows a lump. Only histology shows whether the lump is architecturally disordered, whether its cells are atypical, and whether it has invaded.

How often are uterine polyps cancerous?

The malignancy rate is the number everyone wants and no single study provides perfectly. The reason is selection bias: women referred for polyp removal tend to be older and to have symptoms, which inflates the cancer rate in hospital series. Population-based series give lower numbers.

The size signal is real but should not be overread. A polyp larger than 1.5 centimeters is more likely to contain hyperplasia or carcinoma than a 5-millimeter polyp, but the majority of large polyps are still benign. A 2020 review of hysteroscopic polypectomy series found that roughly 95 percent of removed polyps were benign, and the malignant fraction was concentrated in postmenopausal women with bleeding.

One non-obvious detail: the risk of cancer in a polyp is not the same as the risk of cancer in the uterus. A woman with a benign polyp has essentially the population risk of endometrial cancer. A woman with a polyp showing atypical hyperplasia has a substantially elevated risk and needs more than removal alone.

Symptoms and age: the two strongest signals

Age is the strongest single predictor of malignancy in a polyp. Below 40, malignant polyps are rare enough that case reports dominate the literature. Between 40 and 50, the rate climbs. After menopause, it climbs faster because cumulative mutation exposure and declining progesterone both favor unopposed estrogen signaling.

Symptoms are the second predictor, and they work by selecting for polyps that are larger, older, or actively atypical. Abnormal uterine bleeding — bleeding between periods, bleeding after sex, or any bleeding after menopause — is the most common presentation. Postmenopausal bleeding is a red flag and should always be evaluated, because it is the symptom most strongly associated with endometrial cancer overall.

Other presentations are less specific. A polyp can cause heavy menstrual bleeding, cramping, or a sensation of pressure. Many are found incidentally on imaging done for infertility or another reason. Silent polyps are common, and a silent polyp in a premenopausal woman is usually benign.

Red flags that change the calculus

Most polyps do not need urgent action. Some findings do. The following are the situations where the malignancy probability climbs above the baseline and where the evaluation should move faster.

• Any bleeding after menopause, even a single episode or spotting.
• A polyp larger than 1.5 centimeters in a postmenopausal woman.
• A polyp with a suspicious appearance on hysteroscopy — irregular surface, abnormal vessels, or a friable, easily bleeding base.
• Atypical cells on a prior endometrial biopsy or on cytology.
• A polyp in a woman over 60, regardless of symptoms.
• A polyp in a woman with Lynch syndrome or a strong family history of endometrial or colon cancer.

None of these is a diagnosis. Each is a reason to remove the polyp and examine it under a microscope rather than watch it.

How doctors tell benign from cancerous

The evaluation moves from least invasive to most definitive. A transvaginal ultrasound is usually first. It can show a polyp as a hyperechoic mass within the endometrial cavity, and it measures endometrial thickness. In postmenopausal women, an endometrial thickness of 4 millimeters or less on ultrasound has a high negative predictive value for endometrial cancer, which is why thin linings often reassure.

Ultrasound cannot confirm malignancy in a polyp, though. The definitive step is direct visualization with hysteroscopy and removal of the polyp for histology. Hysteroscopy allows the surgeon to see the surface, take a targeted biopsy, and remove the entire lesion. Saline infusion sonography can also outline polyps and is useful when office hysteroscopy is unavailable.

The pathology report drives decisions. A benign polyp needs nothing further. A polyp with hyperplasia without atypia is usually managed with removal and hormonal follow-up. A polyp with atypical hyperplasia or carcinoma requires staging and treatment by a gynecologic oncologist.

In plain terms: the test that answers "is it cancer" is a microscope, not a picture.

What actually happens after a polyp is found

The practical pathway is fairly uniform, and knowing it reduces the anxiety that comes with the word "polyp."

1. Get the polyp measured and characterized on imaging, and note whether the lining is thickened.
2. If you are postmenopausal with any bleeding, proceed to hysteroscopy and removal without delay.
3. If you are premenopausal and asymptomatic, removal is still reasonable but can be scheduled electively; observation is an option for small polyps in low-risk women.
4. Ask for the pathology report by name. The words "benign," "hyperplasia," and "carcinoma" are the only ones that change management.
5. If atypical hyperplasia or cancer is found, ask for referral to a gynecologic oncologist.
6. After removal, follow up on any bleeding that persists. Recurrence of benign polyps happens in about 10 to 15 percent within a few years, and recurrent bleeding should be re-evaluated.

The timeline: from symptom to diagnosis

The timeline is a rough guide. Systems differ, and in urgent cases — postmenopausal bleeding with a thickened lining — hysteroscopy may happen within days.

Common misconceptions about cancerous polyps

The most common misconception is that a polyp is a precursor to cancer the way a colon polyp can be. That analogy is imperfect. Colon polyps follow a well-mapped adenoma-to-carcinoma sequence with decades of lead time. Uterine polyps are mostly hyperplastic overgrowths, and the majority never progress. The subset that does progress is the subset with atypical cells, not all polyps.

A second misconception is that size alone decides. Size raises probability but does not determine diagnosis. A 2-centimeter polyp in a 35-year-old woman is usually benign, while a 1-centimeter polyp in a 70-year-old with bleeding deserves scrutiny. Age and symptoms weigh more than size.

A third misconception is that removing a polyp prevents cancer. Removal treats the polyp and gives a diagnosis. It does not eliminate the risk of a new lesion forming elsewhere in the endometrium, particularly in women with unopposed estrogen exposure, obesity, or polycystic ovary syndrome.

A fourth, subtler misconception is that a normal ultrasound rules out cancer. A thin lining lowers the probability but does not eliminate it, especially in a woman with a focal polyp or with postmenopausal bleeding.

Hormones, obesity, and the risk modifiers

Exposure to unopposed estrogen is the strongest modifiable risk factor for endometrial pathology, and it applies to polyps as well. Adipose tissue converts androgens to estrone, so obesity raises circulating estrogen. Polycystic ovary syndrome produces chronic anovulation, meaning chronic estrogen without progesterone. Tamoxifen, used in breast cancer treatment, has a partial estrogen-agonist effect on the endometrium and raises the risk of polyps and hyperplasia.

The numbers are worth knowing. Obesity, defined as a body mass index of 30 or higher, is associated with a roughly 2 to 3 times higher risk of endometrial cancer compared with normal weight. Tamoxifen raises the risk of endometrial pathology by a smaller but measurable amount, and the benefit for breast cancer survival usually outweighs it. Diabetes and hypertension are independent risk factors as well.

The protective side is progesterone. Any state that provides regular progesterone exposure — ovulation, combined hormonal contraception, or a progestin-releasing intrauterine device — reduces the risk of endometrial overgrowth. That is why the hormonal context matters as much as the polyp itself.

What to actually do

If you have been told you have a uterine polyp, the concrete steps are straightforward and do not require panic.

Ask whether the polyp is symptomatic and how large it is. Ask whether you are premenopausal or postmenopausal, because that single fact changes the risk estimate by several fold. Request hysteroscopic removal rather than blind dilation and curettage if the polyp is to come out, because direct visualization gives better sampling. Ask for the pathology report and read the diagnosis line. If it says benign, you can stop there. If it says hyperplasia, ask whether it is atypical. If it says carcinoma, ask for oncology referral.

If you have postmenopausal bleeding, do not wait for a scheduled appointment to pass without follow-up. That symptom alone justifies expedited evaluation, and the timeline above exists precisely because it is the highest-yield signal.

If you are in a higher-risk group — over 60, obese, on tamoxifen, or with Lynch syndrome — ask your clinician whether surveillance imaging is appropriate, and how often.

Limits of the evidence

The honest caveat is that the malignancy rates above are ranges, not fixed truths. They depend on the population studied, the method of removal, and whether the series included only symptomatic women. Hospital series overstate risk because they select for referral. Population series understate it because they miss silent polyps that are never removed.

There is also no randomized trial that answers the question "should every polyp be removed?" The recommendation to remove is based on diagnostic value and symptom relief, not on proof that removal prevents cancer. For small, asymptomatic polyps in low-risk premenopausal women, observation is a defensible choice, and the evidence does not clearly favor one path over the other.

What the evidence does support is this: a uterine polyp is usually benign, age and bleeding are the two signals that raise the malignancy probability, and histology is the only test that settles the question. The word "cancerous" belongs to a small minority of polyps, and the pathway from finding to diagnosis is well defined enough that no woman should be left guessing.